14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

Feifei Lu; Wentao Xu; Xiaoye Shi; Honglu Yu; Xingshun Qi

doi:10.2147/IJGM.S427450

14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

Int J Gen Med. 2023 Sep 20:16:4279-4281. doi: 10.2147/IJGM.S427450. eCollection 2023.

Authors

Feifei Lu^#^{1

2}, Wentao Xu^#², Xiaoye Shi^#², Honglu Yu^#², Xingshun Qi^{1

2}

Affiliations

¹ College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People's Republic of China.
² Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People's Republic of China.

^# Contributed equally.

Abstract

Background: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication.

Methods: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included.

Results: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups.

Conclusion: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with H. pylori infection.

Keywords: Helicobacter pylori; bismuth quadruple therapy; efficacy; pantoprazole; vonoprazan.